<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0203256966
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2025
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Zextro
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LINEZOLID
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        600
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1251.4
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Med city" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Med city
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Med City Pharma
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01XX08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Zextro</strong><strong><sup>&reg;</sup></strong><sup> </sup>is an antibiotic of the oxazolidinones group that works by stopping the growth of certain bacteria (germs) that cause infections. It is used to treat pneumonia and some infections in the skin or under the skin. Your doctor will have decided if <strong>Zextro</strong><strong><sup>&reg;</sup></strong> is suitable to treat your infection.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Zextro</strong><strong><sup>&reg;</sup></strong><strong>: </strong></p><p>If you are allergic to linezolid or any of the other ingredients of this medicine.</p><p>If you are taking or have taken within the last 2 weeks any medicines known as monoamine oxidase inhibitors (MAOIs: for example phenelzine, isocarboxazid, selegiline, moclobemide). These medications may be used to treat depression or Parkinson&rsquo;s disease.</p><p>If you are breast-feeding. This is because linezolid passes into breast milk and could affect the baby.</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor, pharmacist or nurse before taking <strong>Zextro</strong><strong><sup>&reg;</sup></strong>:</p><p><strong>Zextro</strong><strong><sup>&reg; </sup></strong>may not be suitable for you if you answer yes<strong> </strong>to any of the following questions. In this case tell your doctor as he/she will need to check your general health and your blood pressure before and during your treatment or may decide that another treatment is better for you.</p><p>Ask your doctor if you are not sure whether these categories apply to you.</p><p>Do you have high blood pressure, whether or not you are taking medicines for this?</p><p>Have you been diagnosed with an overactive thyroid?</p><p>Do you have a tumour of the adrenal glands (phaeochromocytoma) or carcinoid syndrome (caused by tumours of the hormone system with symptoms of diarrhea, flushing of the skin, wheezing)?</p><p>Do you suffer from manic depression, schizoaffective disorder, mental confusion or other mental problems?</p><p><strong>Take special care with Zextro</strong><strong><sup>&reg;</sup></strong></p><p>Tell your doctor before you take this medicine:&nbsp;</p><p>If you bruise and bleed easily.</p><p>If you are anaemic (have low red blood cells).</p><p>If you are prone to getting infections.</p><p>If you have a history of seizures.</p><p>If you have liver problems or kidney problems particularly if you are on dialysis.</p><p>If you have diarrhea.</p><p>Tell your doctor immediately if during treatment you suffer from:</p><p>Problems with your vision such as blurred vision, changes in colour vision, difficulty in seeing detail or if your field of vision becomes restricted.</p><p>Loss of sensitivity in your arms or legs or a sensation of tingling or pricking in your arms or legs.</p><p>You may develop diarrhea while taking or after taking antibiotics, including <strong>Zextro</strong><strong><sup>&reg;</sup></strong>. If this becomes severe or persistent or you notice that your stool contains blood or mucus, you should stop taking <strong>Zextro</strong><strong><sup>&reg; </sup></strong>immediately and consult your doctor. In this situation, you should not take medicines that stop or slow bowel movement.</p><p>Recurrent nausea or vomiting, abdominal pain or rapid breathing.</p><p><strong>Other medicines and Zextro</strong><strong><sup>&reg;</sup></strong></p><p>There is a risk that <strong>Zextro</strong><strong><sup>&reg; </sup></strong>may sometimes interact with certain other medicines to cause side effects such as changes in blood pressure, temperature or heart rate.</p><p>Tell your doctor or pharmacist if you are taking or have recently taken any other medicines.</p><p>Tell your doctor if you are taking or have taken within the last 2 weeks the following medicines as <strong>Zextro</strong><strong><sup>&reg;</sup></strong><sup> </sup>must not be taken if you are already taking these medicines or have taken them recently.</p><p>Monoamine oxidase inhibitors (MAOIs for example phenelzine, isocarboxazid, selegiline, moclobemide). These may be used to treat depression or Parkinson&rsquo;s disease.</p><p>Also tell your doctor if you are taking the following medicines. Your doctor may still decide to give you <strong>Zextro</strong><strong><sup>&reg;</sup></strong>, but will need to check your general health and your blood pressure before and during your treatment. In other cases, your doctor may decide that another treatment is better for you.</p><p>Decongestant cold or flu remedies containing pseudoephedrine or phenylpropanolamine.</p><p>Some medicines used to treat asthma such as salbutamol, terbutaline, fenoterol.</p><p>Certain antidepressants known as tricyclics or SSRIs (selective serotonin reuptake inhibitors). There are many of these, including amitriptyline, citalopram, clomipramine, dosulepin, doxepin, fluoxetine, fluvoxamine, imipramine, lofepramine, paroxetine, sertraline.</p><p>Medicines used to treat migraine such as sumatriptan and zolmitriptan.</p><p>Medicines used to treat sudden, severe allergic reactions such as adrenaline (epinephrine).</p><p>Medicines which increase your blood pressure, such as noradrenaline (norepinephrine), dopamine and dobutamine.</p><p>Medicines used to treat moderate to severe pain, such as pethidine.</p><p>Medicines used to treat anxiety disorders, such as buspirone.</p><p>Medicines that stop blood clotting, such as warfarin.</p><p>An antibiotic called rifampicin.</p><p><strong>Zextro</strong><strong><sup>&reg; </sup></strong><strong>with food, drink and alcohol </strong></p><p>You can take <strong>Zextro</strong><strong><sup>&reg; </sup></strong>either before, during or after a meal.</p><p>Avoid eating large amounts of mature cheese, yeast extracts, or soya bean extracts e.g., soy sauce and drinking alcohol, especially draught beers and wine. This is because <strong>Zextro</strong><strong><sup>&reg; </sup></strong>may react with a substance called tyramine which is naturally present in some foods. This interaction may cause an increase in your blood pressure.</p><p>If you develop a throbbing headache after eating or drinking, tell your doctor, pharmacist or nurse immediately.</p><p><strong>Pregnancy, breast-feeding and fertility </strong></p><p>The effect of <strong>Zextro</strong><strong><sup>&reg; </sup></strong>in pregnant women is not known. Therefore, it should not be taken in pregnancy unless advised by your doctor. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>You should not breast-feed when taking linezolid because it passes into breast milk and could affect the baby.</p><p><strong>Driving and using machines </strong></p><p><strong>Zextro</strong><strong><sup>&reg; </sup></strong>may make you feel dizzy or experience problems with your vision. If this happens, do not drive or operate any machinery. Remember that if you are unwell your ability to drive or operate machinery may be affected.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Adults </strong></p><p>Always take this medicine exactly as described in this leaflet or as your doctor, pharmacist or nurse has told you. Check with your doctor, pharmacist or nurse if you are not sure.</p><p>The recommended dose is one film-coated tablet (600 mg linezolid) twice daily (every twelve hours). Swallow the film-coated tablet whole with some water.</p><p>If you are on kidney dialysis, you should take <strong>Zextro</strong><strong><sup>&reg; </sup></strong>after your dialysis treatment.</p><p>A course of treatment usually lasts 10 to 14 days, but can last up to 28 days. The safety and effectiveness of this medicine have not been established for treatment periods longer than 28 days. Your doctor will decide how long you should be treated.</p><p>While you are taking <strong>Zextro</strong><strong><sup>&reg;</sup></strong>, your doctor should perform regular blood tests to monitor your blood count.</p><p>Your doctor should monitor your eyesight if you take <strong>Zextro</strong><strong><sup>&reg; </sup></strong>for more than 28 days.</p><p><strong>Use in children and adolescents </strong></p><p><strong>Zextro</strong><strong><sup>&reg; </sup></strong>is not normally used to treat children and adolescents (under 18 years old).</p><p><strong>If you take more Zextro</strong><strong><sup>&reg; </sup></strong><strong>than you should </strong></p><p>Tell your doctor or pharmacist immediately.</p><p><strong>If you forget to take Zextro</strong><strong><sup>&reg;</sup></strong></p><p>Take the forgotten tablet as soon as you remember. Take the next film-coated tablet 12 hours after this and continue taking your film-coated tablets every 12 hours. Do not take a double dose to make up for a forgotten film-coated tablet.</p><p><strong>If you stop taking Zextro</strong><strong><sup>&reg;</sup></strong></p><p>Unless your doctor instructs you to stop treatment, it is important to continue taking <strong>Zextro</strong><strong><sup>&reg;</sup></strong>.</p><p>If you stop and your original symptoms come back tell your doctor or pharmacist immediately.&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Tell your doctor, nurse or pharmacist immediately if you notice any of these side effects during your treatment with Zextro</strong><strong><sup>&reg;</sup></strong><strong>: </strong></p><p><strong>The serious side effects (with frequency in brackets) of Linezolid are: </strong></p><p>Severe skin disorder (not known), swelling particularly around the face and neck (not known), wheezing and/or difficulty breathing (not known). This may be the sign of an allergic reaction and it may be necessary for you to stop taking <strong>Zextro</strong><strong><sup>&reg;</sup></strong>. Skin reactions such as red sore skin and flaking (dermatitis) (uncommon), rash (common), itching (common).&nbsp;</p><p>Problems with your vision such as blurred vision (uncommon), changes in colour vision (not known), difficulty in seeing detail (not known) or if your field of vision becomes restricted (rare).</p><p>Severe diarrhea containing blood and/or mucus (antibiotic associated colitis including pseudomembranous colitis), which in rare circumstances may develop into complications that are life-threatening (rare).</p><p>Recurrent nausea or vomiting, abdominal pain or rapid breathing (not known).</p><p>Fits or seizures (uncommon) have been reported with linezolid. You should let your doctor know if you experience agitation, confusion, delirium, rigidity, tremor, incoordination and seizure while also taking antidepressants known as SSRIs (not known).</p><p>Unexplained bleeding or bruising, which may be due to changes in the numbers of certain cells in the blood which may affect blood clotting or lead to anaemia (common).</p><p>Changes in numbers of certain cells in the blood which may affect your ability to fight infection (common) some signs of infection include: any fever (common), sore throat (uncommon), mouth ulcers (uncommon) and tiredness (uncommon).</p><p>Inflammation of the pancreas (uncommon).</p><p>Convulsions (uncommon).</p><p>Transient ischaemic attacks (temporary disturbance of blood flow to the brain causing short term symptoms such as loss of vision, leg and arm weakness, slurring of speech and loss of consciousness) (uncommon).</p><p>&ldquo;Ringing&rdquo; in the ears (tinnitus) (uncommon).</p><p>Numbness, tingling or blurred vision have been reported by patients who have been given linezolid for more than 28 days. If you experience difficulties with your vision you should consult your doctor as soon as possible.</p><p><strong>Other side effects include: </strong></p><p><strong>Common (may affect up to 1 in 10 people): </strong></p><p>Fungal infections especially vaginal or oral &ldquo;thrush&rdquo;.</p><p>Headache.</p><p>Metallic taste in the mouth.</p><p>Diarrhea, nausea or vomiting.</p><p>Changes in some blood test results including those measuring your kidney or liver function or blood sugar levels.</p><p>Difficulty in sleeping.</p><p>Increased blood pressure.</p><p>Anaemia (low red blood cell).</p><p>Dizziness.</p><p>Localised or general abdominal pain.</p><p>Constipation.</p><p>Indigestion.</p><p>Localised pain.</p><p><strong>Uncommon (may affect up to 1 in 100 people): </strong></p><p>Inflammation of the vagina or genital area in women.</p><p>Sensations such as tingling or feeling numb.</p><p>Inflammation of the veins (IV only).</p><p>Swollen, sore, or discoloured tongue.</p><p>A need to urinate more often.</p><p>Chills.</p><p>Feeling thirsty.</p><p>Increased sweating.</p><p>Changes in proteins, salts or enzymes in the blood which measure kidney or liver function.</p><p>Hyponatraemia (low blood sodium levels).</p><p>Kidney failure.</p><p>Reduction in platelets.</p><p>Abdominal bloating.</p><p>Injection site pain.</p><p>Increase in creatinine.</p><p>Stomach pain.</p><p>Changes in heart rate (e.g., increase rate).</p><p><strong>Rare (may affect up to 1 in 1,000 people): </strong></p><p>Superficial tooth discolouration, removable with professional dental cleaning (manual descaling).</p><p><strong>The following side effects have also been reported (Not known: frequency cannot be estimated from the available data): </strong></p><p>Alopecia (hair loss).</p><p>Decrease of the blood cell count.</p><p>Weakness and/or sensory changes.</p><p><strong>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.&nbsp; </strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>Do not use <strong>Zextro</strong><strong><sup>&reg;</sup></strong><strong> </strong>tablets after the expiry date (EXP) which is stated on the blister and the carton.</p><p>The expiry date refers to the last day of that month.</p><p><strong>Zextro</strong><strong><sup>&reg;</sup></strong><strong> </strong>tablets: Store below 30&deg;C.&nbsp;</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Zextro</strong><strong><sup>&reg;</sup></strong><strong> tablets contain</strong></p><p>The active substance is linezolid.</p><p>The other ingredients are Poloxamer, microcrystalline cellulose, sodium starch glycolate, povidone K30, colloidal anhydrous silica, spray dried lactose monohydrate, talc, magnesium stearate, Opadry YS-1-18202-A powder (HPMC/hypromellose, Titanium Dioxide, Macrogol/PEG), Purified water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Zextro® 600 mg tablets are White to off white oval biconvex film coated tablet engraved with H1 on one side and plain on the other side, presented in white opaque HDPE Bottle with cap, 28mm, PP, white CRC, Tamper evident with mounted silica gel desiccant canister 2 gm, intended for oral use.
Pack size: 20 film coated tablets\ pack.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Med City Pharma-KSA.</p><p>1st Industrial city, Phase 5, Jeddah &ndash;KSA.</p><p>Tel: 00966920003288</p><p>Mobile: 00966555786968</p><p>P.O .Box: 4072 - Jeddah 22429</p><p>E-mail: info@medcitypharma.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                10/2023                         
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>زيكسترو</strong><strong><sup>&reg;</sup></strong> هو مضاد حيوي من مجموعة أوكسازوليدينون والتي تعمل عن طريق وقف نمو نوع معين من البكتيريا (الجراثيم) التي تسبب الالتهابات. و يستعمل لعلاج الالتهاب الرئوي و بعض التهابات الجلد أو ما تحت الجلد. سيقرر طبيبك إذا كان <strong>زيكسترو</strong><strong><sup>&reg; </sup></strong>ملائم لعلاج الالتهاب الذي تعاني منه.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب</strong><strong> </strong><strong>عدم</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>زيكسترو</strong><strong><sup> &reg; </sup></strong><strong>في</strong><strong> </strong><strong>الحالات</strong><strong> </strong><strong>التالية</strong><strong>:</strong></p><p dir="RTL">إذا كنت تعاني من تحسس للينزوليد أو لأي مكونات أخرى في هذا الدواء.</p><p dir="RTL">إذا كنت تتناول أو تناولت خلال الأسبوعين الماضيين أي أدوية تسمى مثبطات أوكسيديز أحادي الأمين (مثل فينيلزين، أيزوكاربوكسازيد، سيليجيلين، موكلوبيميد). قد تستعمل هذه الأدوية لعلاج الاكتئاب أو مرض باركنسون.</p><p dir="RTL">إذا كنت مرضعة. و ذلك لأنه يتم إفراز لينزوليد في حليب الثدي و من الممكن أن يؤثر على الطفل.</p><p dir="RTL"><strong>الاحتياطات</strong><strong> </strong><strong>والمحاذير</strong></p><p dir="RTL">تحدث مع طبيبك، الصيدلي أو الممرض قبل تناول <strong>زيكسترو</strong><strong><sup>&reg;</sup></strong>.</p><p dir="RTL">قد يكون <strong>زيكسترو</strong><strong><sup>&reg; </sup></strong>غير مناسب لك، في حال كانت إجابتك نعم على أي من الأسئلة التالية، في هذه الحالة أخبر طبيبك بذلك، حيث سيحتاج هو/هي التأكد من حالتك الصحية العامة و من ضغط الدم قبل و خلال فترة العلاج أو قد يقرر أن علاج آخر هو الأفضل لك.</p><p dir="RTL">اسأل طبيبك إذا لم تكن متأكد أي من هذه الفئات تناسبك.</p><p dir="RTL">هل تعاني من ارتفاع ضغط الدم، سواء كنت تتناول أدوية لعلاج ذلك أم لا؟</p><p dir="RTL">هل تم تشخيصك سابقا بأنك تعاني من فرط نشاط الغدة الدرقية ؟</p><p dir="RTL">هل تعاني من ورم في الغدة الكظرية (ورم القواتم) أو متلازمة التناذر السرطاناني (يحدث نتيجة ورم في الجهاز الهرموني مصاحب لأعراض&nbsp; مثل الإسهال، احمرار الجلد أو أزيز تنفسي)؟</p><p dir="RTL">هل تعاني من الاكتئاب الهوسي، الاضطراب الفصامي العاطفي، ارتباك عقلي، أو أي مشاكل عقلية أخرى؟</p><p dir="RTL"><strong>اتخاذ</strong><strong> </strong><strong>احتياطات</strong><strong> </strong><strong>خاصة</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>زيكسترو</strong><strong><sup>&reg;&nbsp; </sup></strong></p><p dir="RTL">أخبر طبيبك قبل تناول هذا الدواء:</p><p dir="RTL">إذا كنت تتعرض للكدمات و النزيف بسهولة.</p><p dir="RTL">إذا كنت مصاب بفقر الدم (انخفاض عدد خلايا الدم الحمراء).</p><p dir="RTL">إذا كنت عرضة للإصابة بالالتهابات.</p><p dir="RTL">إذا سبق وعانيت من نوبات الصرع.</p><p dir="RTL">إذا كنت تعاني من مشاكل في الكبد أو الكلى، خاصة إذا كنت تخضع للديلزة الدموية.</p><p dir="RTL">إذا كنت تعاني من إسهال.</p><p dir="RTL"><strong>أخبر</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>على</strong><strong> </strong><strong>الفور</strong><strong> </strong><strong>إذا</strong><strong> </strong><strong>حصل</strong><strong> </strong><strong>لديك</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>من</strong><strong> </strong><strong>الحالات</strong><strong> </strong><strong>التالية</strong><strong> </strong><strong>خلال</strong><strong> </strong><strong>فترة</strong><strong> </strong><strong>العلاج</strong><strong>:</strong></p><p dir="RTL">مشاكل في الرؤية مثل: ضبابية الرؤية، تغير في رؤية الألوان، صعوبة في رؤية التفاصيل أو إذا أصبح مجال الرؤيا لديك محدود.</p><p dir="RTL">فقدان الإحساس في الذراعين أو الساقين أو الإحساس بوخز خفيف أو تنميل في الذراعين أو الساقين.</p><p dir="RTL">قد تعاني من الإسهال خلال أو بعد تناولك المضادات الحيوية بما في ذلك <strong>زيكسترو</strong><strong><sup>&reg;</sup></strong>. إذا أصبح الإسهال حاد أو مستمر أو إذا لاحظت بأن البراز يحتوي على الدم أو المخاط، يجب عليك التوقف عن تناول <strong>زيكسترو</strong><strong><sup>&reg;</sup></strong><strong> </strong>فورا و استشارة طبيبك. في هذه الحالة، يجب عليك عدم تناول الأدوية التي تثبط أو تبطئ من حركة الأمعاء.</p><p dir="RTL">الشعور بالغثيان أو القيء المتكرر أو آلام في البطن أو التنفس السريع.</p><p dir="RTL"><strong>أدوية</strong><strong> </strong><strong>أخرى</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>زيكسترو</strong><strong><sup>&reg;</sup></strong></p><p dir="RTL">هناك خطورة من أن يتفاعل <strong>زيكسترو</strong><strong><sup>&reg;</sup></strong> أحيانا مع أدوية معينة أخرى مما يؤدي إلى ظهور آثار جانبية مثل تغيرات في ضغط الدم، درجة حرارة الجسم، أو معدل سرعة نبضات القلب.</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرا أي أدوية أخرى.</p><p dir="RTL">أخبر طبيبك إذا كنت تتناول أو تناولت خلال الأسبوعين الماضيين أي من الأدوية التالية، حيث أنه يجب عدم تناول <strong>زيكسترو</strong><strong><sup>&reg;</sup></strong> إذا كنت تتناول هذه الأدوية أو تناولتها مؤخرا.</p><p dir="RTL">مثبطات أوكسيديز أحادي الأمين (مثل: فينيلزين، أيزوكاربوكسازيد، سيليجيلين، موكلوبيميد). قد تستعمل هذه الأدوية لعلاج الإكتئاب أو مرض باركنسون.</p><p dir="RTL">أخبر طبيبك أيضا إذا كنت تتناول الأدوية التالية. قد يقرر طبيبك الاستمرار بتناول <strong>زيكسترو</strong><strong><sup>&reg;</sup></strong>، لكن ستحتاج التأكد من الصحة العامة و ضغط الدم قبل و خلال فترة علاجك، في حالات أخرى قد يقرر طبيبك أن علاج آخر هو الأفضل لك.</p><p dir="RTL">أدوية لعلاج الاحتقان الناتج عن الزكام أو الإنفلونزا و التي تحتوي على سودوإفدرين أو فينيل بروبانولامين.</p><p dir="RTL">بعض الأدوية التي تستعمل لعلاج مرض الربو مثل سالبيوتامول، تيربوتالين، فينوتيرول.</p><p dir="RTL">مضادات اكتئاب معينة تعرف بمضادات الاكتئاب ثلاثية الحلقة أو مثبطات إعادة امتصاص السيروتونين الانتقائية. هناك العديد منها و تشمل أميتربتيلين، سيتالوبرام، كلوميبرامين، دوسوليبين، دوكسيبين، فلوكسيتين، فلوڤوكسامين، إيميبرامين، لوفيبرامين، باروكسيتين، سيرترالين.</p><p dir="RTL">أدوية تستعمل لعلاج الشقيقة مثل سوماتريبتان و زولميتريبتان.</p><p dir="RTL">أدوية تستعمل لعلاج التفاعلات التحسسية المفاجئة و الحادة مثل أدرينالين (إبينفرين).</p><p dir="RTL">الأدوية التي تسبب ارتفاع في ضغط الدم، مثل نورأدرينالين (نورإبينفرين)، دوبامين، دوبيوتامين.</p><p dir="RTL">الأدوية التي تستعمل لعلاج الألم المتوسط إلى الحاد مثل بيثيدين.</p><p dir="RTL">الأدوية التي تستعمل لعلاج اضطرابات القلق مثل بوسبيرون.</p><p dir="RTL">الأدوية التي تستعمل للوقاية من تجلط الدم مثل الوارفارين.</p><p dir="RTL">مضاد حيوي يسمى ريفامبيسين.</p><p dir="RTL"><strong>تناول</strong><strong> </strong><strong>زيكسترو</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>مع</strong><strong> </strong><strong>الطعام،</strong><strong> </strong><strong>الشراب</strong><strong> </strong><strong>والكحول</strong></p><p dir="RTL">بإمكانك تناول <strong>زيكسترو</strong><strong><sup>&reg;</sup></strong> إما قبل أو خلال أو بعد وجبة الطعام.</p><p dir="RTL">تجنب تناول كمية كبيرة من الجبن الناضج، مستخلصات الخميرة، أو مستخلصات فول الصويا مثل: صلصة الصويا و شرب الكحول، خاصة البيرة و النبيذ، وذلك لأن <strong>زيكسترو</strong><strong><sup>&reg; </sup></strong>قد يتفاعل مع مادة أخرى تسمى تيرامين والتي تتواجد بشكل طبيعي في بعض الأطعمة. هذا التفاعل قد يسبب ارتفاع في ضغط الدم.</p><p dir="RTL">إذا عانيت من صداع على شكل نبض قوي بعد تناول الطعام أو الشراب، أخبر طبيبك، الصيدلي أو الممرض فورا.</p><p dir="RTL"><strong>الحمل،</strong><strong> </strong><strong>الرضاعة</strong><strong> </strong><strong>الطبيعية</strong><strong> </strong><strong>و</strong><strong> </strong><strong>الخصوبة</strong></p><p dir="RTL">إن تأثير<strong> </strong><strong>زيكسترو</strong><strong><sup>&reg; </sup></strong>على المرأة الحامل غير معروف. لذلك يجب عدم تناوله خلال فترة الحمل ما لم ينصح به الطبيب.</p><p dir="RTL">إذا كنت حامل أو مرضعة، تعتقدين بأنك حامل أو تخططين للحمل، استشري طبيبك أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL">يجب عليك عدم الإرضاع في حال تناول لينزوليد لأنه يفرز في حليب الثدي و من الممكن أن يؤثر على الطفل.</p><p dir="RTL"><strong>القيادة</strong><strong> </strong><strong>و</strong><strong> </strong><strong>استخدام</strong><strong> </strong><strong>الآلات</strong></p><p dir="RTL">قد يجعلك <strong>زيكسترو</strong><strong><sup>&reg;</sup></strong> تشعر بالدوار أو تعاني من مشاكل في الرؤية، إذا حصل لديك هذا عليك تجنب القيادة أو تشغيل أي آلة.</p><p dir="RTL">تذكر ذلك، قد تتأثر قدرتك على القيادة أو تشغيل الآلات إذا لم تكن على ما يرام.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>البالغون</strong></p><p dir="RTL">دائما تناول هذا الدواء تماما كما ذكر في هذه النشرة أو كما أخبرك طبيبك، الصيدلي أو الممرض. يجب التأكد من الطبيب، الصيدلي أو الممرض إذا لم تكن متأكدا.</p><p dir="RTL">الجرعة الموصى بها هي قرص واحد مغلف (600 ملغم لينزوليد) مرتين يوميا (كل 12 ساعة). قم بتناول القرص المغلف كاملا مع بعض الماء.</p><p dir="RTL">إذا كنت تخضع للديلزة الكلوية، يجب عليك تناول <strong>زيكسترو</strong><strong><sup>&reg; </sup></strong>بعد الخضوع للديلزة.</p><p dir="RTL">عادة يستمر العلاج لمدة 10 إلى 14 يوم، لكنه قد يستمر لمدة 28 يوما. لم تثبت سلامة و فعالية تناول هذا الدواء لمدة تزيد عن 28 يوما، سيقرر طبيبك المدة اللازمة لعلاج حالتك.</p><p dir="RTL">خلال فترة تناولك <strong>زيكسترو</strong><strong><sup>&reg;</sup></strong><strong>،</strong><strong> </strong>يجب على طبيبك القيام بفحوصات دم منتظمة لمراقبة تعداد خلايا الدم.</p><p dir="RTL">يجب على طبيبك مراقبة حالة الرؤية لديك، إذا كنت تتناول <strong>زيكسترو</strong><strong><sup>&reg;</sup></strong> لأكثر من 28 يوم.</p><p dir="RTL"><strong>الاستعمال</strong><strong> </strong><strong>للأطفال</strong><strong> </strong><strong>و</strong><strong> </strong><strong>المراهقين</strong></p><p dir="RTL">لا يتم استعمال <strong>زيكسترو</strong><strong><sup>&reg;</sup></strong><sup> </sup>عادة لعلاج الأطفال والمراهقين (الذين تقل أعمارهم عن 18 عاما).</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>تناولت</strong><strong> </strong><strong>زيكسترو</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>أكثر</strong><strong> </strong><strong>مما</strong><strong> </strong><strong>يجب</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي فورا.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>نسيت</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>جرعة</strong><strong> </strong><strong>زيكسترو</strong><strong><sup>&reg;</sup></strong></p><p dir="RTL">تناول الجرعة التي نسيتها فور تذكرك، تناول القرص المغلف الذي يليه بعد 12 ساعة من تناول الجرعة و استمر بتناول القرص المغلف كل 12 ساعة&nbsp; لا تتناول جرعة مضاعفة لتعويض القرص المغلف الذي نسيته.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>توقفت</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>زيكسترو</strong><strong><sup>&reg;</sup></strong></p><p dir="RTL">من الضروري الاستمرار في تناول <strong>زيكسترو</strong><strong><sup>&reg;</sup></strong>، ما لم يخبرك الطبيب بالتوقف عن العلاج.</p><p dir="RTL">إذا أوقفت العلاج و عادت الأعراض الأصلية للظهور، أخبر طبيبك أو الصيدلي بذلك فورا.</p><p dir="RTL">إذا كان لديك أية أسئلة إضافية عن استعمال هذا الدواء، اسأل طبيبك، الصيدلي أو الممرض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثار جانبية، على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL"><strong>أخبر</strong><strong> </strong><strong>طبيبك،</strong><strong> </strong><strong>الممرض</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>الصيدلي</strong><strong>&nbsp; </strong><strong>فورا</strong><strong> </strong><strong>إذا</strong><strong> </strong><strong>لاحظت</strong><strong> </strong><strong>حدوث</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>من</strong><strong> </strong><strong>الآثار</strong><strong> </strong><strong>الجانبية</strong><strong> </strong><strong>التالية</strong><strong> </strong><strong>خلال</strong><strong> </strong><strong>فترة</strong><strong> </strong><strong>علاجك</strong><strong> </strong><strong>باستعمال</strong><strong> </strong><strong>زيكسترو</strong><strong><sup>&reg;</sup></strong><strong>:</strong></p><p dir="RTL"><strong>الآثار</strong><strong> </strong><strong>الجانبية</strong><strong> </strong><strong>الخطيرة</strong><strong> (</strong><strong>مع</strong><strong> </strong><strong>ذكر</strong><strong> </strong><strong>تكرار</strong><strong> </strong><strong>حدوثها</strong><strong> </strong><strong>بين</strong><strong> </strong><strong>الأقواس</strong><strong>) </strong><strong>عند</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>لينزوليد</strong><strong> </strong><strong>هي</strong><strong>:</strong></p><p dir="RTL">اضطرابات جلدية حادة (غير معروفة)، تورم خصوصا حول الوجه و الرقبة (غير معروفة)، أزيز تنفسي و/أو صعوبة في التنفس (غير معروفة)، قد تكون هذه علامة لتفاعل تحسسي و قد يكون من الضروري التوقف عن تناول <strong>زيكسترو</strong><strong><sup>&reg;</sup></strong>.<strong><sup> </sup>&nbsp;</strong>تفاعلات جلدية مثل تقرح جلدي أحمر اللون وتقشر الجلد (التهاب الجلد) (غير شائعة)، طفح (شائع)، حكة (شائعة).</p><p dir="RTL">مشاكل في الرؤية مثل ضبابية الرؤية (غير شائعة)، تغيرات في رؤية الألوان (غير معروفة)، صعوبة في رؤية التفاصيل (غير معروفة) أو إذا أصبح مجال الرؤيا لديك محدود (نادرة).</p><p dir="RTL">إسهال حاد مصاحب للدم و/أو المخاط (التهاب القولون المرتبط بتناول مضاد حيوي معين ويشمل التهاب القولون الغشائي الكاذب)، والذي في ظروف نادرة قد يحصل مضاعفات تسبب الوفاة (نادرة).</p><p dir="RTL">الغثيان أو القئ المتكرر أو آلام في البطن أو التنفس السريع (غير معروفة).</p><p dir="RTL">تم تسجيل حدوث نوبات ظهور أعراض مفاجئة أو نوبات صرع (غير شائعة) عند استعمال لينزوليد، يجب عليك أن تخبر طبيبك إذا عانيت من هياج، ارتباك، هذيان، تصلب، رجفان، عدم تناسق و نوبات الصرع، أيضا خلال تناولك لمضادات الاكتئاب و التي تعرف بمثبطات إعادة امتصاص السيروتونين الانتقائية (غير معروفة).</p><p dir="RTL">نزيف أو كدمات غير مفسرة، و التي قد تكون بسبب حدوث تغيرات في عدد خلايا معينة في الدم و التي قد تؤثر على تجلط الدم أو تسبب فقر الدم (شائعة).</p><p dir="RTL">تغيرات في عدد خلايا معينة في الدم و التي قد تؤثر على قدرتك في مقاومة الالتهابات (شائعة) تتضمن بعض علامات الالتهاب: أي نوع من أنواع الحمى (شائعة)، التهاب الحلق (غير شائعة)، تقرحات في الفم (غير شائعة)، الشعور بالتعب (غير شائعة).</p><p dir="RTL">التهاب البنكرياس (غير شائعة).</p><p dir="RTL">تشنجات (غير شائعة).</p><p dir="RTL">نوبة نقص التروية المؤقتة (اضطراب مؤقت في تدفق الدم للدماغ مما يسبب أعراض قصيرة المدى مثل: فقدان البصر، الشعور بالضعف في القدمين و اليدين، تلعثم في الكلام و فقدان الوعي) (غير شائعة).</p><p dir="RTL">رنين في الأذنين (طنين) (غير شائعة).</p><p dir="RTL">تم تسجيل حدوث التنميل، الإحساس بوخز خفيف أو ضبابية الرؤية عند المرضى الذين تم إعطاؤهم لينزوليد لمدة تزيد عن 28 يوم، إذا عانيت من صعوبات في الرؤية، يجب عليك استشارة طبيبك بأسرع وقت ممكن.</p><p dir="RTL"><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>أخرى</strong><strong> </strong><strong>تتضمن</strong><strong>:</strong></p><p dir="RTL"><strong>شائعة</strong><strong> (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> 1 </strong><strong>أو</strong><strong> </strong><strong>أقل</strong><strong> </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 10 </strong><strong>أشخاص</strong><strong>):</strong></p><p dir="RTL">التهاب فطري خاصة الالتهاب المهبلي أو الفموي (القلاع).</p><p dir="RTL">صداع.</p><p dir="RTL">الشعور بمذاق معدني في الفم .</p><p dir="RTL">إسهال، الشعور بالغثيان أو القئ.</p><p dir="RTL">تغيرات في نتائج بعض فحوصات الدم و التي تتضمن فحوصات وظائف الكلى أو الكبد أو مستوى السكر في الدم.</p><p dir="RTL">صعوبة في النوم.</p><p dir="RTL">ارتفاع في ضغط الدم.</p><p dir="RTL">فقر الدم (انخفاض في عدد خلايا الدم الحمراء).</p><p dir="RTL">الشعور بالدوار.</p><p dir="RTL">ألم في البطن موضعي أو عام.</p><p dir="RTL">إمساك.</p><p dir="RTL">عسر هضم.</p><p dir="RTL">ألم موضعي.</p><p dir="RTL"><strong>غير</strong><strong> </strong><strong>شائعة</strong><strong> (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> 1 </strong><strong>أو</strong><strong> </strong><strong>أقل</strong><strong> </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 100 </strong><strong>شخص</strong><strong>):</strong></p><p dir="RTL">التهابات مهبلية أو في المنطقة التناسلية للنساء.</p><p dir="RTL">الإحساس بوخز خفيف أو التنميل.</p><p dir="RTL">التهاب في الأوردة (الحقن الوريدي فقط).</p><p dir="RTL">تورم أو تقرح أو تغير في لون اللسان.</p><p dir="RTL">الحاجة للتبول بشكل أكثر من المعتاد.</p><p dir="RTL">قشعريرة.</p><p dir="RTL">الشعور بالعطش.</p><p dir="RTL">فرط التعرق.</p><p dir="RTL">تغيرات في نتائج فحص البروتينات، الأملاح أو الإنزيمات في الدم و التي تقيس وظيفة الكلى أو الكبد.</p><p dir="RTL">انخفاض مستوى الصوديوم في الدم.</p><p dir="RTL">قصور وظيفة الكلى.</p><p dir="RTL">نقص في تعداد الصفيحات الدموية.</p><p dir="RTL">انتفاخ في البطن.</p><p dir="RTL">ألم في مكان الحقن.</p><p dir="RTL">زيادة في مستوى الكرياتينين.</p><p dir="RTL">ألم في المعدة.</p><p dir="RTL">تغيرات في معدل سرعة نبضات القلب (مثل زيادة معدل سرعة نبضات القلب).</p><p dir="RTL"><strong>نادرة</strong><strong> (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> 1 </strong><strong>أو</strong><strong> </strong><strong>أقل</strong><strong> </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 1000 </strong><strong>شخص</strong><strong>):</strong></p><p dir="RTL">تغير سطحي في لون الأسنان، من الممكن إزالته عن طريق تنظيفه بطريقة احترافية عند طبيب الأسنان (إزالة الترسبات يدويا).</p><p dir="RTL"><strong>تم</strong><strong> </strong><strong>تسجيل</strong><strong> </strong><strong>الآثار</strong><strong> </strong><strong>الجانبية</strong><strong> </strong><strong>التالية</strong><strong> </strong><strong>أيضا</strong><strong> (</strong><strong>غير</strong><strong> </strong><strong>معروفة</strong><strong> </strong><strong>لا</strong><strong> </strong><strong>يمكن</strong><strong> </strong><strong>تقدير</strong><strong> </strong><strong>تكرار</strong><strong> </strong><strong>حدوثها</strong><strong> </strong><strong>من</strong><strong> </strong><strong>المعلومات</strong><strong> </strong><strong>المتوفرة</strong><strong>):</strong></p><p dir="RTL">الصلع (تساقط الشعر).</p><p dir="RTL">انخفاض في عدد خلايا الدم الحمراء.</p><p dir="RTL">الشعور بالضعف و/أو تغيرات في الإحساس.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>حصل</strong><strong> </strong><strong>لديك</strong><strong> </strong><strong>آثار</strong><strong> </strong><strong>جانبية،</strong><strong> </strong><strong>تحدث</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>الصيدلي</strong><strong>. </strong><strong>هذا</strong><strong> </strong><strong>يتضمن</strong><strong> </strong><strong>الآثار</strong><strong> </strong><strong>الجانبية</strong><strong> </strong><strong>غير</strong><strong> </strong><strong>المذكورة</strong><strong> </strong><strong>في</strong><strong> </strong><strong>هذه</strong><strong> </strong><strong>النشرة</strong><strong>.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ بعيدا عن متناول الأطفال و نظرهم.</p><p dir="RTL">لا تستعمل أقراص <strong>زيكسترو</strong><strong><sup>&reg;</sup></strong><strong> </strong>بعد تاريخ انتهاء الصلاحية المذكورعلى الشريط و العلبة الخارجية.</p><p dir="RTL">تاريخ الانتهاء يشير إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL"><strong>زيكسترو</strong><strong><sup>&reg; </sup></strong>أقراص: يحفظ&nbsp; بدرجة حرارة دون 30 &deg;م.</p><p dir="RTL">يجب أن لا يتم التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. وسوف تساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي لينزوليد.</p><p dir="RTL">المكونات الأخرى هي بولوكسامير، ميكروكريستالين سيليلوز، جلايكولات نشا الصوديوم، بوڤيدون K30، سيليكا</p><p dir="RTL">غروية لامائية، رذاذ لاكتوز مونوهيدرات مجفف، تلك، مغنيسيوم ستيرات، مسحوق أوبادري YS-1-18202-A- (هيدروكسي بروبيل ميثيل سيليلوز/هيبروميلوز، ثاني أكسيد التيتانيوم، ماكروجول/بولي إيثيلين جلايكول)، ماء نقي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>زيكسترو</strong><strong><sup>&reg;</sup></strong> <strong>600 </strong><strong>ملغم</strong> هي أقراص مغلفة، ذات لون أبيض إلى كريمي، بیضاویة الشكل، محدبة الوجهين محفور على أحد الأوجه H1، معبأة في عبوة بولي إيثيلين عالي الكثافة بيضاء اللون غير شفافة ذات غطاء قطره 28 مم، من البولي بروبيلين أبيض اللون مقاوم للفتح من قبل الأطفال، يدل على التلاعب ويحتوي على سيليكا مجففة 2 غم، معد للاستعمال عن طریق الفم.</p><p dir="RTL"><strong>حجم</strong><strong> </strong><strong>العبوة</strong><strong>:</strong> 20 قرص مغلف/ عبوة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مدينة الدواء للصناعات الدوائية - المملكة العربية السعودية.</p><p dir="RTL">المدينة الصناعية الأولى، المرحلة الخامسة، جدة - المملكة العربية السعودية.</p><p dir="RTL">هاتف: 00966920003288</p><p dir="RTL">جوال: 00966555786968</p><p dir="RTL">ص.ب: 4072 - جدة 22429</p><p>بريد الكتروني: info@medcitypharma.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            10/2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zextro® 600 mg Film Coated Tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zextro® 600 mg: Each film-coated tablet contains 600 mg Linezolid.

For a full list of excipients: see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablets.

Zextro® 600 mg tablets are White to off white oval biconvex film coated tablet engraved with H1 on one side and plain on the other side, presented in white opaque HDPE Bottle with cap, 28mm, PP, white CRC, Tamper evident with mounted silica gel desiccant canister 2 gm, intended for oral use.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Nosocomial pneumonia.</strong></p><p><strong>Community acquired pneumonia.</strong></p><p><strong>Zextro<sup>&reg;</sup></strong> is indicated in adults for the treatment of community acquired pneumonia and nosocomial pneumonia when known or suspected to be caused by susceptible Gram positive bacteria. In determining whether <strong>Zextro<sup>&reg; </sup></strong>is an appropriate treatment, the results of microbiological tests or information on the prevalence of resistance to antibacterial agents among Gram positive bacteria should be taken into consideration (see section 5.1 for the appropriate organisms).</p><p>Linezolid is not active against infections caused by Gram negative pathogens. Specific therapy against Gram negative organisms must be initiated concomitantly if a Gram negative pathogen is documented or suspected.</p><p><strong>Complicated skin and soft tissue infections (see section 4.4)</strong></p><p><strong>Zextro<sup>&reg; </sup></strong>is indicated in adults for the treatment of complicated skin and soft tissue infections&nbsp;<strong>only</strong>&nbsp;when microbiological testing has established that the infection is known to be caused by susceptible Gram positive bacteria.</p><p>Linezolid is not active against infections caused by Gram negative pathogens. Linezolid should only be used in patients with complicated skin and soft tissue infections with known or possible co-infection with Gram negative organisms if there are no alternative treatment options available (see section 4.4). In these circumstances treatment against Gram negative organisms&nbsp;must be initiated concomitantly.</p><p>Linezolid should only be initiated in a hospital environment and after consultation with a relevant specialist such as a microbiologist or infectious diseases specialist.</p><p><strong>Consideration should be given to official guidance on the appropriate use of antibacterial agents</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><strong>Zextro<sup>&reg;</sup></strong> solution for infusion, film-coated tablets may be used as initial therapy. Patients who commence treatment on the parenteral formulation may be switched to either oral presentation when clinically indicated. In such circumstances, no dose adjustment is required as linezolid has an oral bioavailability of approximately 100%.</p><p><em><u>Recommended dosage and duration of treatment for adults:</u></em></p><p>The duration of treatment is dependent on the pathogen, the site of infection and its severity, and on the patient&#39;s clinical response.</p><p>The following recommendations for duration of therapy reflect those used in the clinical trials. Shorter treatment regimens may be suitable for some types of infection but have not been evaluated in clinical trials.</p><p>The maximum treatment duration is 28 days. The safety and effectiveness of linezolid when administered for periods longer than 28 days have not been established. (See section 4.4).</p><p>No increase in the recommended dosage or duration of treatment is required for infections associated with concurrent bacteraemia.</p><p>The dose recommendation for the solution for infusion and the tablets are identical and are as follows:</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:top"><p><strong>Infections</strong></p></td><td style="vertical-align:top"><p><strong>Dosage</strong></p></td><td style="vertical-align:top"><p><strong>Duration of treatment</strong></p></td></tr><tr><td style="vertical-align:top"><p>Nosocomial pneumonia</p></td><td rowspan="2" style="vertical-align:top"><p>600 mg twice daily</p></td><td rowspan="3" style="vertical-align:top"><p>10-14 Consecutive days</p></td></tr><tr><td style="vertical-align:top"><p>Community acquired pneumonia</p></td></tr><tr><td style="vertical-align:top"><p>Complicated skin and soft tissue infections</p></td><td style="vertical-align:top"><p>600 mg twice daily</p></td></tr></tbody></table><p><em><u>Paediatric population:</u></em></p><p>The safety and efficacy of linezolid in children aged (&lt; 18 years old) has not been established. Currently available data are described in section 4.8, 5.1, and 5.2 but no recommendation on a posology can be made</p><p><em><u>Elderly</u></em><u>:</u></p><p>No dose adjustment is required.</p><p><em><u>Renal impairment</u></em><u>:</u></p><p>No dose adjustment is required (see sections 4.4 and 5.2).</p><p><em><u>Severe renal impairment (i.e. CL</u></em><em><u><sub>CR</sub></u></em><em><u>&nbsp;&lt; 30 ml/min)</u></em>:</p><p>No dose adjustment is required. Due to the unknown clinical significance of higher exposure (up to 10 fold) to the two primary metabolites of linezolid in patients with severe renal insufficiency, linezolid should be used with special caution in these patients and only when the anticipated benefit is considered to outweigh the theoretical risk.</p><p>As approximately 30% of a linezolid dose is removed during 3 hours of haemodialysis, linezolid should be given after dialysis in patients receiving such treatment. The primary metabolites of linezolid are removed to some extent by haemodialysis, but the concentrations of these metabolites are still very considerably higher following dialysis than those observed in patients with normal renal function or mild to moderate renal insufficiency.</p><p>Therefore, linezolid should be used with special caution in patients with severe renal insufficiency who are undergoing dialysis and only when the anticipated benefit is considered to outweigh the theoretical risk.</p><p>To date, there is no experience of linezolid administration to patients undergoing continuous ambulatory peritoneal dialysis (CAPD) or alternative treatments for renal failure (other than haemodialysis).</p><p><em><u>Hepatic impairment</u></em><u>:</u></p><p>No dose adjustment is required. However, there are limited clinical data and it is recommended that linezolid should be used in such patients only when the anticipated benefit is considered to outweigh the theoretical risk (see sections 4.4 and 5.2).</p><p><u>Method of administration:</u></p><p>The recommended linezolid dosage should be administered orally twice daily.</p><p>Route of administration: Oral use.</p><p>The film-coated tablets may be taken with or without food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to linezolid or to any of the excipients listed in section 6.1.
Linezolid should not be used in patients taking any medicinal product which inhibits monoamine oxidases A or B (e.g. phenelzine, isocarboxazid, selegiline, moclobemide) or within two weeks of taking any such medicinal product.
Unless there are facilities available for close observation and monitoring of blood pressure, linezolid should not be administered to patients with the following underlying clinical conditions or on the following types of concomitant medications:
- Patients with uncontrolled hypertension, phaeochromocytoma, carcinoid, thyrotoxicosis, bipolar depression, schizoaffective disorder, acute confusional states.
- Patients taking any of the following medications: serotonin re-uptake inhibitors (see section 4.4), tricyclic antidepressants, serotonin 5-HT1 receptor agonists (triptans), directly and indirectly acting sympathomimetic agents (including the adrenergic bronchodilators, pseudoephedrine and phenylpropanolamine), vasopressive agents (e.g. epinephrine, norepinephrine), dopaminergic agents (e.g. dopamine, dobutamine), pethidine or buspirone.
Animal data suggest that linezolid and its metabolites may pass into breast milk and, accordingly, breast-feeding should be discontinued prior to and throughout administration (see section 4.6).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Myelosuppression</u></p><p>Myelosuppression (including anaemia, leucopenia, pancytopenia and thrombocytopenia) has been reported in patients receiving linezolid. In cases where the outcome is known, when linezolid was discontinued, the affected haematologic parameters have risen toward pretreatment levels. The risk of these effects appears to be related to the duration of treatment. Elderly patients treated with linezolid may be at greater risk of experiencing blood dyscrasias than younger patients. Thrombocytopenia may occur more commonly in patients with severe renal insufficiency, whether or not on dialysis. Therefore, close monitoring of blood counts is recommended in patients who: have pre-existing anaemia, granulocytopenia or thrombocytopenia; are receiving concomitant medications that may decrease haemoglobin levels, depress blood counts or adversely affect platelet count or function; have severe renal insufficiency; receive more than 10-14 days of therapy. Linezolid should be administered to such patients only when close monitoring of haemoglobin levels, blood counts and platelet counts is possible.</p><p>If significant myelosuppression occurs during linezolid therapy, treatment should be stopped unless it is considered absolutely necessary to continue therapy, in which case intensive monitoring of blood counts and appropriate management strategies should be implemented.</p><p>In addition, it is recommended that complete blood counts (including haemoglobin levels, platelets, and total and differentiated leucocyte counts) should be monitored&nbsp;<u>weekly</u>&nbsp;in patients who receive linezolid regardless of baseline blood count.</p><p>In compassionate use studies, a higher incidence of serious anaemia was reported in patients receiving linezolid for more than the maximum recommended duration of 28 days. These patients more often required blood transfusion. Cases of anaemia requiring blood transfusion have also been reported post marketing, with more cases occurring in patients who received linezolid therapy for more than 28 days.</p><p>Cases of sideroblastic anaemia have been reported post-marketing. Where time of onset was known, most patients had received linezolid therapy for more than 28 days. Most patients fully or partially recovered following discontinuation of linezolid with or without treatment for their anaemia.</p><p><u>Mortality imbalance in a clinical trial in patients with catheter-related Gram positive bloodstream infections</u></p><p>Excess mortality was seen in patients treated with linezolid, relative to vancomycin/dicloxacillin/oxacillin, in an open-label study in seriously ill patients with intravascular catheter-related infections [78/363 (21.5%) vs 58/363 (16.0%)]. The main factor influencing the mortality rate was the Gram positive infection status at baseline. Mortality rates were similar in patients with infections caused purely by Gram positive organisms (odds ratio 0.96; 95% confidence interval: 0.58-1.59) but were significantly higher (p=0.0162) in the linezolid arm in patients with any other pathogen or no pathogen at baseline (odds ratio 2.48; 95% confidence interval: 1.38-4.46). The greatest imbalance occurred during treatment and within 7 days following discontinuation of study drug. More patients in the linezolid arm acquired Gram negative pathogens during the study and died from infection caused by Gram negative pathogens and polymicrobial infections. Therefore, in complicated skin and soft tissue infections linezolid should only be used in patients with known or possible co-infection with Gram negative organisms if there are no alternative treatment options available (see section 4.1). In these circumstances treatment against Gram negative organisms must be initiated concomitantly.</p><p><u>Antibiotic-associated diarrhea and colitis</u></p><p>Antibiotic-associated diarrhea and antibiotic-associated colitis, including pseudomembranous colitis and&nbsp;<em>Clostridium difficile</em>-associated diarrhea, has been reported in association with the use of nearly all antibiotics including linezolid and may range in severity from mild diarrhea to fatal colitis. Therefore, it is important to consider this diagnosis in patients who develop serious diarrhea during or after the use of linezolid. If antibiotic-associated diarrhea or antibiotic-associated colitis is suspected or confirmed, ongoing treatment with antibacterial agents, including linezolid, should be discontinued and adequate therapeutic measures should be initiated immediately. Drugs inhibiting peristalsis are contraindicated in this situation.</p><p><u>Lactic acidosis</u></p><p>Lactic acidosis has been reported with the use of linezolid. Patients who develop signs and symptoms of metabolic acidosis including recurrent nausea or vomiting, abdominal pain, a low bicarbonate level, or hyperventilation while receiving linezolid should receive immediate medical attention. If lactic acidosis occurs, the benefits of continued use of linezolid should be weighed against the potential risks.</p><p><u>Mitochondrial dysfunction</u></p><p>Linezolid inhibits mitochondrial protein synthesis. Adverse events, such as lactic acidosis, anaemia and neuropathy (optic and peripheral), may occur as a result of this inhibition; these events are more common when the drug is used longer than 28 days.</p><p><u>Serotonin syndrome</u></p><p>Spontaneous reports of serotonin syndrome associated with the co-administration of linezolid and serotonergic agents, including antidepressants such as selective serotonin reuptake inhibitors (SSRIs) have been reported. Co-administration of linezolid and serotonergic agents is therefore contraindicated (see section 4.3) except where administration of linezolid and concomitant serotonergic agents is essential. In those cases patients should be closely observed for signs and symptoms of serotonin syndrome such as cognitive dysfunction, hyperpyrexia, hyperreflexia and incoordination. If signs or symptoms occur physicians should consider discontinuing either one or both agents; if the concomitant serotonergic agent is withdrawn, discontinuation symptoms can occur.</p><p><u>Peripheral and optic neuropathy</u></p><p>Peripheral neuropathy, as well as optic neuropathy and optic neuritis sometimes progressing to loss of vision, have been reported in patients treated with linezolid; these reports have primarily been in patients treated for longer than the maximum recommended duration of 28 days.</p><p>All patients should be advised to report symptoms of visual impairment, such as changes in visual acuity, changes in colour vision, blurred vision, or visual field defect. In such cases, prompt evaluation is recommended with referral to an ophthalmologist as necessary. If any patients are taking <strong>Zextro<sup>&reg; </sup></strong>for longer than the recommended 28 days, their visual function should be regularly monitored.</p><p>If peripheral or optic neuropathy occurs, the continued use of <strong>Zextro<sup>&reg; </sup></strong>should be weighed against the potential risks.</p><p>There may be an increased risk of neuropathies when linezolid is used in patients currently taking or who have recently taken antimycobacterial medications for the treatment of tuberculosis.</p><p><u>Convulsions</u></p><p>Convulsions have been reported to occur in patients when treated with linezolid. In most of these cases, a history of seizures or risk factors for seizures was reported. Patients should be advised to inform their physician if they have a history of seizures.</p><p><u>Monoamine oxidase inhibitors</u></p><p>Linezolid is a reversible, non-selective inhibitor of monoamine oxidase (MAOI); however, at the doses used for antibacterial therapy, it does not exert an anti-depressive effect. There are very limited data from drug interaction studies and on the safety of linezolid when administered to patients with underlying conditions and/or on concomitant medications which might put them at risk from MAO inhibition. Therefore, linezolid is not recommended for use in these circumstances unless close observation and monitoring of the recipient is possible (see sections 4.3 and 4.5).</p><p><u>Use with tyramine-rich foods</u></p><p>Patients should be advised against consuming large amounts of tyramine-rich foods (see section 4.5).</p><p><u>Superinfection</u></p><p>The effects of linezolid therapy on normal flora have not been evaluated in clinical trials.</p><p>The use of antibiotics may occasionally result in an overgrowth of non-susceptible organisms. For example, approximately 3% of patients receiving the recommended linezolid doses experienced drug-related candidiasis during clinical trials. Should superinfection occur during therapy, appropriate measures should be taken.</p><p><u>Special populations</u></p><p>Linezolid should be used with special caution in patients with severe renal insufficiency and only when the anticipated benefit is considered to outweigh the theoretical risk (see sections 4.2 and 5.2).</p><p>It is recommended that linezolid should be given to patients with severe hepatic insufficiency only when the perceived benefit outweighs the theoretical risk (see sections 4.2 and 5.2).</p><p><u>Impairment of fertility</u></p><p>Linezolid reversibly decreased fertility and induced abnormal sperm morphology in adult male rats at exposure levels approximately equal to those expected in humans; possible effects of linezolid on the human male reproductive system are not known (see section 5.3).</p><p><u>Clinical trials</u></p><p>The safety and effectiveness of linezolid when administered for periods longer than 28 days have not been established.</p><p>Controlled clinical trials did not include patients with diabetic foot lesions, decubitus or ischaemic lesions, severe burns or gangrene. Therefore, experience in the use of linezolid in the treatment of these conditions is limited.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Monoamine oxidase inhibitors</u></p><p>Linezolid is a reversible, non-selective inhibitor of monoamine oxidase (MAOI). There are very limited data from drug interaction studies and on the safety of linezolid when administered to patients on concomitant medications that might put them at risk from MAO inhibition. Therefore, linezolid is not recommended for use in these circumstances unless close observation and monitoring of the recipient is possible (see sections 4.3 and 4.4).</p><p><u>Potential interactions producing elevation of blood pressure</u></p><p>In normotensive healthy volunteers, linezolid enhanced the increases in blood pressure caused by pseudoephedrine and phenylpropanolamine hydrochloride. Co-administration of linezolid with either pseudoephedrine or phenylpropanolamine resulted in mean increases in systolic blood pressure of the order of 30-40 mmHg, compared with 11-15 mmHg increases with linezolid alone, 14-18 mmHg with either pseudoephedrine or phenylpropanolamine alone and 8-11 mmHg with placebo. Similar studies in hypertensive subjects have not been conducted. It is recommended that doses of drugs with a vasopressive action, including dopaminergic agents, should be carefully titrated to achieve the desired response when co-administered with linezolid.</p><p><u>Potential serotonergic interactions</u></p><p>The potential drug-drug interaction with dextromethorphan was studied in healthy volunteers. Subjects were administered dextromethorphan (two 20 mg doses given 4 hours apart) with or without linezolid. No serotonin syndrome effects (confusion, delirium, restlessness, tremors, blushing, diaphoresis and hyperpyrexia) have been observed in normal subjects receiving linezolid and dextromethorphan.</p><p>Post marketing experience: there has been one report of a patient experiencing serotonin syndrome-like effects while taking linezolid and dextromethorphan which resolved on discontinuation of both medications.</p><p>During clinical use of linezolid with serotonergic agents, including antidepressants such as selective serotonin reuptake inhibitors (SSRIs), cases of serotonin syndrome have been reported. Therefore, while co-administration is contraindicated (see section 4.3), management of patients for whom treatment with linezolid and serotonergic agents is essential, is described in section 4.4.</p><p><u>Use with tyramine-rich foods</u></p><p>No significant pressor response was observed in subjects receiving both linezolid and less than 100 mg tyramine. This suggests that it is only necessary to avoid ingesting excessive amounts of food and beverages with a high tyramine content (e.g. mature cheese, yeast extracts, undistilled alcoholic beverages and fermented soya bean products such as soy sauce).</p><p><u>Drugs metabolised by cytochrome P450</u></p><p>Linezolid is not detectably metabolised by the cytochrome P450 (CYP) enzyme system and it does not inhibit any of the clinically significant human CYP isoforms (1A2, 2C9, 2C19, 2D6, 2E1, 3A4). Similarly, linezolid does not induce P450 isoenzymes in rats. Therefore, no CYP450-induced drug interactions are expected with linezolid.</p><p><u>Rifampicin</u></p><p>The effect of rifampicin on the pharmacokinetics of linezolid was studied in sixteen healthy adult male volunteers administered linezolid 600 mg twice daily for 2.5 days with and without rifampicin 600 mg once daily for 8 days. Rifampicin decreased the linezolid Cmax and AUC by a mean 21% [90% CI, 15, 27] and a mean 32% [90% CI, 27, 37], respectively. The mechanism of this interaction and its clinical significance are unknown.</p><p><u>Warfarin</u></p><p>When warfarin was added to linezolid therapy at steady-state, there was a 10% reduction in mean maximum INR on co-administration with a 5% reduction in AUC INR. There are insufficient data from patients who have received warfarin and linezolid to assess the clinical significance, if any, of these findings.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are limited data from the use of linezolid in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). A potential risk for humans exists.</p><p>Linezolid should not be used during pregnancy unless clearly necessary i.e. only if the potential benefit outweighs the theoretical risk.</p><p><u>Breast-feeding</u></p><p>Animal data suggest that linezolid and its metabolites may pass into breast milk and, accordingly, breast-feeding should be discontinued prior to and throughout administration.</p><p><u>Fertility</u></p><p>In animal studies, linezolid caused a reduction in fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients should be warned about the potential for dizziness or symptoms of visual impairment (as described in section 4.4 and 4.8) whilst receiving linezolid and should be advised not to drive or operate machinery if any of these symptoms occurs.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The table below provides a listing of adverse drug reactions with frequency based on all-causality data from clinical studies that enrolled more than 2,000 adult patients who received the recommended linezolid doses for up to 28 days.</p><p>Those most commonly reported were diarrhea (8.4%), headache (6.5%), nausea (6.3%) and vomiting (4.0%).</p><p>The most commonly reported drug-related adverse events which led to discontinuation of treatment were headache, diarrhea, nausea and vomiting. About 3% of patients discontinued treatment because they experienced a drug-related adverse event.</p><p>Additional adverse reactions reported from post-marketing experience are included in the table with frequency category &#39;Not known&#39;, since the actual frequency cannot be estimated from the available data.</p><p>The following undesirable effects have been observed and reported during treatment with linezolid with the following frequencies: Very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); Not known (cannot be estimated from the available data)</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p><strong>(&ge;1/100 to &lt;1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong>(&ge;1/1,000 to &lt;1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p><strong>(&ge;1/10,000 to &lt;1/1,000)</strong></p></td><td style="vertical-align:top"><p><strong>Very Rare</strong></p><p><strong>(&lt;1/10,000)</strong></p></td><td style="vertical-align:top"><p><strong>Frequency not known (cannot be estimated from available data)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top"><p>candidiasis, oral candidiasis, vaginal candidiasis, fungal infections</p></td><td style="vertical-align:top"><p>vaginitis</p></td><td style="vertical-align:top"><p>antibiotic-associated colitis, including pseudomembranous colitis*</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Blood and the lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>anaemia*<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>leucopenia*, neutropenia, thrombocytopenia*, eosinophilia</p></td><td style="vertical-align:top"><p>pancytopenia*</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>myelosuppression*, sideroblastic anaemia*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>anaphylaxis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>hyponatraemia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>lactic acidosis*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>insomnia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>headache, taste perversion (metallic taste), dizziness</p></td><td style="vertical-align:top"><p>convulsions*, hypoaesthesia, paraesthesia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>serotonin syndrome**, peripheral neuropathy*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>blurred vision*</p></td><td style="vertical-align:top"><p>changes in visual field defect*</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>optic neuropathy*, optic neuritis*, loss of vision*, changes in visual acuity*, changes in colour vision*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>tinnitus</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>arrhythmia (tachycardia)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>hypertension</p></td><td style="vertical-align:top"><p>transient ischaemic attacks, phlebitis, thrombophlebitis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>diarrhoea, nausea, vomiting, localised or general abdominal pain, constipation, dyspepsia</p></td><td style="vertical-align:top"><p>pancreatitis, gastritis, abdominal distention, dry mouth, glossitis, loose stools, stomatitis, tongue discolouration or disorder</p></td><td style="vertical-align:top"><p>superficial tooth discolouration</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Hepato-biliary disorders</strong></p></td><td style="vertical-align:top"><p>abnormal liver function test; increased AST, ALT or alkaline phosphatase</p></td><td style="vertical-align:top"><p>increased total bilirubin</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>pruritus, rash</p></td><td style="vertical-align:top"><p>urticaria, dermatitis, diaphoresis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>bullous disorders such as those described as Stevens-Johnson syndrome and toxic epidermal necrolysis, angioedema, alopecia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top"><p>increased BUN</p></td><td style="vertical-align:top"><p>renal failure, increased creatinine, polyuria</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>vulvovaginal disorder</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>fever, localised pain</p></td><td style="vertical-align:top"><p>chills, fatigue, injection site pain, increased thirst</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p><u>Chemistry</u></p><p>Increased LDH, creatine kinase, lipase, amylase or non fasting glucose. Decreased total protein, albumin, sodium or calcium. Increased or decreased potassium or bicarbonate.</p><p><u>Haematology</u></p><p>Increased neutrophils or eosinophils. Decreased haemoglobin, haematocrit or red blood cell count. Increased or decreased platelet or white blood cell counts.</p></td><td style="vertical-align:top"><p><u>Chemistry</u></p><p>Increased sodium or calcium. Decreased non fasting glucose. Increased or decreased chloride.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;&nbsp;</p><p><u>Haematology</u></p><p>Increased reticulocyte count.</p><p>Decreased neutrophils.</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table><p>* See section 4.4.</p><p>** See sections 4.3 and 4.5</p><p>&dagger; See below</p><p>The following adverse reactions to linezolid were considered to be serious in rare cases: localised abdominal pain, transient ischaemic attacks and hypertension.</p><p>&dagger;In controlled clinical trials where linezolid was administered for up to 28 days, 2.0% of the patients reported anaemia. In a compassionate use program of patients with life-threatening infections and underlying co-morbidities, the percentage of patients who developed anaemia when receiving linezolid for &le; 28 days was 2.5% (33/1326) as compared with 12.3% (53/430) when treated for &gt;28 days. The proportion of cases reporting drug-related serious anaemia and requiring blood transfusion was 9% (3/33) in patients treated for &le; 28 days and 15% (8/53) in those treated for &gt;28 days.</p><p><u>Paediatric population</u></p><p>Safety data from clinical studies based on more than 500 paediatric patients (from birth to 17 years) do not indicate that the safety profile of linezolid for paediatric patients differs from that for adult patients.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific antidote is known.</p><p>No cases of overdose have been reported. However, the following information may prove useful:</p><p>Supportive care is advised together with maintenance of glomerular filtration. Approximately 30% of a linezolid dose is removed during 3 hours of haemodialysis, but no data are available for the removal of linezolid by peritoneal dialysis or haemoperfusion. The two primary metabolites of linezolid are also removed to some extent by haemodialysis.</p><p>Signs of toxicity in rats following doses of 3000 mg/kg/day linezolid were decreased activity and ataxia whilst dogs treated with 2000 mg/kg/day experienced vomiting and tremors.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other antibacterials, ATC code: J 01 X X 08.</p><p><u>General properties</u></p><p>Linezolid is a synthetic, antibacterial agent that belongs to a new class of antimicrobials, the oxazolidinones. It has in vitro activity against aerobic Gram positive bacteria and anaerobic micro-organisms. Linezolid selectively inhibits bacterial protein synthesis via a unique mechanism of action. Specifically, it binds to a site on the bacterial ribosome (23S of the 50S subunit) and prevents the formation of a functional 70S initiation complex which is an essential component of the translation process.</p><p>The in vitro postantibiotic effect (PAE) of linezolid for&nbsp;<em>Staphylococcus aureus</em>&nbsp;was approximately 2 hours. When measured in animal models, the in vivo PAE was 3.6 and 3.9 hours for&nbsp;<em>Staphylococcus aureus</em>&nbsp;and&nbsp;<em>Streptococcus pneumoniae,</em>&nbsp;respectively. In animal studies, the key pharmacodynamic parameter for efficacy was the time for which the linezolid plasma level exceeded the minimum inhibitory concentration (MIC) for the infecting organism.</p><p><u>Breakpoints</u></p><p>Minimum inhibitory concentration (MIC) breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) for staphylococci and enterococci are Susceptible &le; 4mg/L and Resistant &gt;4 mg/L. For streptococci (including&nbsp;<em>S. pneumoniae</em>) the breakpoints are Susceptible &le; 2 mg/L and Resistant &gt;4 mg/L.</p><p>Non-species related MIC breakpoints are Susceptible &le; 2 mg/L and Resistant &gt; 4 mg/L. Non-species related breakpoints have been determined mainly on the basis of PK/PD data and are independent of MIC distributions of specific species. They are for use only for organisms that have not been given a specific breakpoint and not for those species where susceptibility testing is not recommended.</p><p><u>Susceptibility</u></p><p>The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:top"><p><strong>Category</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Susceptible organisms</u></p><p><strong>Gram positive aerobes:</strong></p><p><em>Enterococcus faecalis</em></p><p><em>Enterococcus faecium*</em></p><p><em>Staphylococcus aureus</em>*</p><p>Coagulase negative staphylococci</p><p><em>Streptococcus agalactiae*</em></p><p><em>Streptococcus pneumoniae*</em></p><p><em>Streptococcus pyogenes*</em></p><p>Group C streptococci</p><p>Group G streptococci</p><p><strong>Gram positive anaerobes:</strong></p><p><em>Clostridium perfringens</em></p><p><em>Peptostreptococcus anaerobius</em></p><p><em>Peptostreptococcus&nbsp;</em>species</p></td></tr><tr><td style="vertical-align:top"><p><u>Resistant organisms</u></p><p><em>Haemophilus influenzae</em></p><p><em>Moraxella catarrhalis</em></p><p><em>Neisseria</em>&nbsp;species</p><p><em>Enterobacteriaceae</em></p><p><em>Pseudomonas</em>&nbsp;species</p></td></tr></tbody></table><p>*Clinical efficacy has been demonstrated for susceptible isolates in approved clinical indications.</p><p>Whereas linezolid shows some in vitro activity against&nbsp;<em>Legionella, Chlamydia pneumoniae&nbsp;</em>and<em>&nbsp;Mycoplasma pneumoniae</em>, there are insufficient data to demonstrate clinical efficacy.</p><p><u>Resistance</u></p><p><em><u>Cross resistance</u></em></p><p>Linezolid&#39;s mechanism of action differs from those of other antibiotic classes. In vitro studies with clinical isolates (including methicillin-resistant staphylococci, vancomycin-resistant enterococci, and penicillin- and erythromycin-resistant streptococci) indicate that linezolid is usually active against organisms which are resistant to one or more other classes of antimicrobial agents.</p><p>Resistance to linezolid is associated with point mutations in the 23S rRNA.</p><p>As documented with other antibiotics when used in patients with difficult to treat infections and/or for prolonged periods, emergent decreases in susceptibility have been observed with linezolid. Resistance to linezolid has been reported in enterococci, Staphylococcus aureus and coagulase negative staphylococci. This generally has been associated with prolonged courses of therapy and the presence of prosthetic materials or undrained abscesses. When antibiotic-resistant organisms are encountered in the hospital it is important to emphasize infection control policies.</p><p><u>Information from clinical trials</u></p><p>Studies in the paediatric population:</p><p>In an open study, the efficacy of linezolid (10 mg/kg q8h) was compared to vancomycin (10- 15mg/kg q6- 24h) in treating infections due to suspected or proven resistant gram-positive pathogens(including nosocomial pneumonia, complicated skin and skin structure infections, catheter related bacteraemia, bacteraemia of unknown source, and other infections), in children from birth to 11 years. Clinical cure rates in the clinically evaluable population were 89.3% (134/150) and 84.5% (60/71) for linezolid and vancomycin, respectively (95%CI: -4.9, 14.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Zextro<sup>&reg; </sup></strong>primarily contains (s)-linezolid which is biologically active and is metabolised to form inactive derivatives.</p><p><u>Absorption</u></p><p>Linezolid is rapidly and extensively absorbed following oral dosing. Maximum plasma concentrations are reached within 2 hours of dosing. Absolute oral bioavailability of linezolid (oral and intravenous dosing in a crossover study) is complete (approximately 100%). Absorption is not significantly affected by food and absorption from the oral suspension is similar to that achieved with the film-coated tablets.</p><p>Plasma linezolid Cmax and Cmin (mean and [SD]) at steady-state following twice daily intravenous dosing of 600 mg have been determined to be 15.1 [2.5] mg/l and 3.68 [2.68] mg/l, respectively.</p><p>In another study following oral dosing of 600 mg twice daily to steady-state, Cmax and Cmin were determined to be 21.2 [5.8] mg/l and 6.15 [2.94] mg/l, respectively. Steady-state conditions are achieved by the second day of dosing.</p><p><u>Distribution</u></p><p>Volume of distribution at steady-state averages at about 40-50 litres in healthy adults and approximates to total body water. Plasma protein binding is about 31% and is not concentration dependent.</p><p>Linezolid concentrations have been determined in various fluids from a limited number of subjects in volunteer studies following multiple dosing. The ratio of linezolid in saliva and sweat relative to plasma was 1.2:1.0 and 0.55:1.0, respectively. The ratio for epithelial lining fluid and alveolar cells of the lung was 4.5:1.0 and 0.15:1.0, when measured at steady-state Cmax, respectively. In a small study of subjects with ventricular-peritoneal shunts and essentially non-inflamed meninges, the ratio of linezolid in cerebrospinal fluid to plasma at Cmax was 0.7:1.0 after multiple linezolid dosing.</p><p><u>Biotransformation</u></p><p>Linezolid is primarily metabolised by oxidation of the morpholine ring resulting mainly in the formation of two inactive open-ring carboxylic acid derivatives; the aminoethoxyacetic acid metabolite (PNU-142300) and the hydroxyethyl glycine metabolite (PNU-142586). The hydroxyethyl glycine metabolite (PNU-142586) is the predominant human metabolite and is believed to be formed by a non-enzymatic process. The aminoethoxyacetic acid metabolite (PNU-142300) is less abundant. Other minor, inactive metabolites have been characterised.</p><p><u>Elimination</u></p><p>In patients with normal renal function or mild to moderate renal insufficiency, linezolid is primarily excreted under steady-state conditions in the urine as PNU-142586 (40%), parent drug (30%) and PNU-142300 (10%). Virtually no parent drug is found in the faeces whilst approximately 6% and 3% of each dose appears as PNU-142586 and PNU-142300, respectively. The elimination half-life of linezolid averages at about 5-7 hours.</p><p>Non-renal clearance accounts for approximately 65% of the total clearance of linezolid. A small degree of non-linearity in clearance is observed with increasing doses of linezolid. This appears to be due to lower renal and non-renal clearance at higher linezolid concentrations. However, the difference in clearance is small and is not reflected in the apparent elimination half-life.</p><p><em><u>Special populations</u></em></p><p><em><u>Renal impairment</u></em><u>:</u>&nbsp;After single doses of 600 mg, there was a 7-8 fold increase in exposure to the two primary metabolites of linezolid in the plasma of patients with severe renal insufficiency (i.e. creatinine clearance &lt; 30 ml/min). However, there was no increase in AUC of parent drug. Although there is some removal of the major metabolites of linezolid by haemodialysis, metabolite plasma levels after single 600 mg doses were still considerably higher following dialysis than those observed in patients with normal renal function or mild to moderate renal insufficiency.</p><p>In 24 patients with severe renal insufficiency, 21 of whom were on regular haemodialysis, peak plasma concentrations of the two major metabolites after several days dosing were about 10 fold those seen in patients with normal renal function. Peak plasma levels of linezolid were not affected.</p><p>The clinical significance of these observations has not been established as limited safety data are currently available (see sections 4.2 and 4.4).</p><p><em><u>Hepatic impairment</u></em><u>:</u>&nbsp;Limited data indicate that the pharmacokinetics of linezolid, PNU-142300 and PNU-142586 are not altered in patients with mild to moderate hepatic insufficiency (i.e. Child-Pugh class A or B). The pharmacokinetics of linezolid in patients with severe hepatic insufficiency (i.e. Child-Pugh class C) have not been evaluated. However, as linezolid is metabolised by a non-enzymatic process, impairment of hepatic function would not be expected to significantly alter its metabolism (see sections 4.2 and 4.4).</p><p><em><u>Paediatric population (&lt; 18 years old)</u></em>: There are insufficient data on the safety and efficacy of linezolid in children and adolescents (&lt; 18 years old) and therefore, use of linezolid in this age group is not recommended.(see section 4.2). Further studies are needed to establish safe and effective dosage recommendations. Pharmacokinetic studies indicate that after single and multiple doses in children (1 week to 12 years), linezolid clearance (based on kg body weight) was greater in paediatric patients than in adults, but decreased with increasing age.</p><p>In children 1 week to 12 years old, administration of 10 mg/kg every 8 hours daily gave exposure approximating to that achieved with 600 mg twice daily in adults.</p><p>In neonates up to 1 week of age, the systemic clearance of linezolid (based on kg body weight) increases rapidly in the first week of life. Therefore, neonates given 10 mg/kg every 8 hours daily will have the greatest systemic exposure on the first day after delivery. However, excessive accumulation is not expected with this dosage regimen during the first week of life as clearance increases rapidly over that period.</p><p>In adolescents (12 to 17 years old), linezolid pharmacokinetics were similar to that in adults following a 600mg dose. Therefore, adolescents administered 600 mg every 12 hours daily will have similar exposure to that observed in adults receiving the same dosage.</p><p>In paediatric patients with ventriculoperitoneal shunts who were administered linezolid 10mg/kg either 12 hourly or 8 hourly, variable cerebrospinal fluid (CSF) linezolid concentrations were observed following either single or multiple dosing of linezolid. Therapeutic concentrations were not consistently achieved or maintained in the CSF. Therefore, the use of linezolid for the empirical treatment of paediatric patients with central nervous system infections is not recommended.</p><p><em><u>Elderly</u></em>: The pharmacokinetics of linezolid are not significantly altered in elderly patients aged 65 and over.</p><p><em><u>Female patients</u></em>: Females have a slightly lower volume of distribution than males and the mean clearance is reduced by approximately 20% when corrected for body weight. Plasma concentrations are higher in females and this can partly be attributed to body weight differences. However, because the mean half-life of linezolid is not significantly different in males and females, plasma concentrations in females are not expected to substantially rise above those known to be well tolerated and, therefore, dose adjustments are not required.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Linezolid decreased fertility and reproductive performance of male rats at exposure levels approximately equal to those in humans. In sexually mature animals these effects were reversible. However, these effects did not reverse in juvenile animals treated with linezolid for nearly the entire period of sexual maturation. Abnormal sperm morphology in testis of adult male rats, and epithelial cell hypertrophy and hyperplasia in the epididymis were noted. Linezolid appeared to affect the maturation of rat spermatozoa. Supplementation of testosterone had no effect on linezolid-mediated fertility effects. Epididymal hypertrophy was not observed in dogs treated for 1 month, although changes in the weights of prostate, testes and epididymis were apparent.</p><p>Reproductive toxicity studies in mice and rats showed no evidence of a teratogenic effect at exposure levels 4 times or equivalent, respectively, to those in humans. The same linezolid concentrations caused maternal toxicity in mice and were related to increased embryo death including total litter loss, decreased fetal body weight and an exacerbation of the normal genetic predisposition to sternal variations in the strain of mice. In rats, slight maternal toxicity was noted at exposures lower than clinical exposures. Mild fetal toxicity, manifested as decreased fetal body weights, reduced ossification of sternebrae, reduced pup survival and mild maturational delays were noted. When mated, these same pups showed evidence of a reversible dose-related increase in pre-implantation loss with a corresponding decrease in fertility. In rabbits, reduced fetal body weight occurred only in the presence of maternal toxicity (clinical signs, reduced body weight gain and food consumption) at low exposure levels 0.06 times compared to the expected human exposure based on AUCs. The species is known to be sensitive to the effects of antibiotics.</p><p>Linezolid and its metabolites are excreted into the milk of lactating rats and the concentrations observed were higher than those in maternal plasma.</p><p>Linezolid produced reversible myelosuppression in rats and dogs.</p><p>In rats administered linezolid orally for 6 months, non-reversible, minimal to mild axonal degeneration of sciatic nerves was observed at 80 mg/kg/day; minimal degeneration of the sciatic nerve was also observed in 1 male at this dose level at a 3-month interim necropsy. Sensitive morphologic evaluation of perfusion-fixed tissues was conducted to investigate evidence of optic nerve degeneration. Minimal to moderate optic nerve degeneration was evident in 2 of 3 male rats after 6 months of dosing, but the direct relationship to drug was equivocal because of the acute nature of the finding and its asymmetrical distribution. The optic nerve degeneration observed was microscopically comparable to spontaneous unilateral optic nerve degeneration reported in aging rats and may be an exacerbation of common background change.</p><p>Preclinical data, based on conventional studies of repeated-dose toxicity and genotoxicity, revealed no special hazard for humans beyond those addressed in other sections of this Summary of Product Characteristics. Carcinogenicity / oncogenicity studies have not been conducted in view of the short duration of dosing and lack of genotoxicity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Poloxamer, microcrystalline cellulose, sodium starch glycolate, povidone K30, colloidal anhydrous silica, spray dried lactose monohydrate, talc, magnesium stearate, Opadry YS-1-18202-A powder (HPMC/hypromellose, Titanium Dioxide, Macrogol/PEG), Purified water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Zextro<sup>&reg; </sup>600 mg tablets are </strong>White to off white oval biconvex film coated tablet engraved with H1 on one side and plain on the other side, presented in white opaque HDPE Bottle with cap, 28mm, PP, white CRC, Tamper evident with mounted silica gel desiccant canister 2 gm, intended for oral use.</p><p><strong>Pack size:</strong> 20 Film Coated Tablets/Bottle.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Med City Pharma-KSA.
1st Industrial city, Phase 5, Jeddah –KSA.
Tel: 00966920003288
Mobile: 00966555786968
P.O .Box: 4072 - Jeddah 22429
E-mail: info@medcitypharma.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                10/2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>